Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAPER: Eltrombopag Tapering to Induce Sustained Remission in Adult Primary ITP After First-line Steroids
jRCT2080225175Phase 2Completed
- Sponsor
- Novartis
- Start
- Apr 2020
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of eltrombopag in immune thrombocytopenia (ITP), sponsored by Novartis. Started Apr 2020; status: completed.
02
Drugs
eltrombopag
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on jRCT2080225175.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225175.